Farlac

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Farlac

Farlac: An Overview of Its Identity and Therapeutic Use

Property Description
Active Ingredient Lactulose
Form Oral Solution or Powder for Solution
Pharmacological Class Osmotic Laxative, Ammonium Detoxicant
Common Use Management of Chronic Constipation
Origin Semi-synthetic disaccharide

Farlac is a medicine whose active ingredient is Lactulose, a compound classified primarily as an osmotic laxative. It is most commonly found as a thick liquid oral solution. The primary purpose of this medication is to treat and manage chronic constipation, and it is frequently used when dietary changes are not sufficient.

Lactulose is clinically recognized for its unique ability to draw water into the colon, which softens the stool and gently promotes bowel movements. This mechanism ensures a non-irritating, localized action within the digestive tract.


What Is Farlac’s Origin and Composition?

Farlac's active ingredient, Lactulose, is a unique synthetic disaccharide created by chemically modifying the natural milk sugar, lactose. This structure is critical because the human digestive system lacks the necessary enzyme to break it down.

Lactulose is considered non-absorbable in the small intestine, allowing it to reach the colon intact where it exerts its effects locally. This localized action is a key aspect of the medicine's pharmacological safety profile.


What Conditions Is Farlac Used to Manage?

The general therapeutic purpose of Farlac is mainly centered on the long-term management of chronic constipation. It provides relief by promoting regular, comfortable bowel function.

Beyond its common use as a laxative, Farlac plays an essential clinical role in managing a severe liver complication known as Hepatic Encephalopathy (HE). In this context, it functions as an ammonium detoxicant by helping to reduce the absorption of toxins, such as ammonia, from the blood in the colon.

Regulatory References

  1. NIH - Lactulose Overview

What side effects are possible with Farlac?

The official safety profile of Farlac (Lactulose) is strictly defined by government regulatory documents, which classify adverse reactions based on frequency and affected body system. The adverse reactions are primarily related to its action within the gastrointestinal tract.

Classification Adverse Reaction
Very Common (ge 1/10) Flatulence (abdominal distension)
Common (ge 1/100 to < 1/10) Abdominal pain, Diarrhea, Nausea, Vomiting
Uncommon (ge 1/1,000 to < 1/100) Electrolyte imbalance

These reactions fall mainly under Gastrointestinal Disorders. Flatulence is officially noted to be more likely at the start of treatment and typically diminishes after a few days.

The most significant documented safety concern, particularly with high-dose or prolonged use, is the risk of clinically relevant electrolyte imbalance (e.g., severe hypokalemia). This serious adverse reaction can result from severe or persistent fluid loss (diarrhea or vomiting) and is specifically noted in patients receiving treatment for Hepatic Encephalopathy (HE).

Specific safety considerations apply to certain populations and conditions. Official labeling restricts use in individuals with known or suspected gastrointestinal obstruction or galactosemia. Furthermore, older adults and patients with an impaired general condition receiving high doses are noted as being at an increased risk of dehydration and electrolyte disturbance. Prolonged administration (over six months) may require regulatory-mandated monitoring for electrolyte levels.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Farlac (Lactulose) is primarily documented by severe gastrointestinal manifestations, specifically intense diarrhea and pronounced abdominal cramping or pain. This excessive gastrointestinal activity poses a serious systemic risk: severe fluid and electrolyte depletion, which can involve metabolic disturbances such as hypokalemia (low potassium) and hypernatremia (high sodium).

For patients receiving high-dose, long-term treatment, such as for hepatic encephalopathy, an overdose-induced electrolyte imbalance may aggravate the underlying condition. The regulatory information notes that children may also be at an increased risk of dehydration and electrolyte imbalance following overdosage.


When to Seek Immediate Medical Help

Regulatory guidance mandates that in a case of suspected drug overdose, individuals must contact a healthcare practitioner, hospital emergency department, or a Poison Control Center immediately, even if initial symptoms are not yet apparent. Treatment is defined as symptomatic and supportive, and the management focuses on fluid and electrolyte replacement to correct the metabolic imbalance. As no specific antidote is known, the priority is correcting the fluid loss. Treatment should be immediately terminated or reduced upon confirmation of overdosage.

Therapeutic Uses of Farlac

The therapeutic application of Farlac (Lactulose) is used across two primary domains of symptomatic relief. This medication is generally applied in contexts marked by increased discomfort or systemic burden.

The medication is commonly used to help manage symptoms related to persistent Bowel Irregularity and to provide support for the systemic issues associated with Hepatic Encephalopathy (HE). It is considered relevant for easing symptom clusters that may become intense or disruptive, such as hard stools, painful defecation, confusion, and disorientation. The application of this medication across these domains may assist with maintaining functional stability and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Constipation

Farlac is commonly used when dietary changes and lifestyle modifications have been ineffective in managing the chronic symptoms of infrequent, difficult bowel movements.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Farlac

Regulatory documentation defines precise population groups for whom Farlac use is permitted, restricted, or prohibited. The medicine is primarily approved for adults for both chronic constipation and the management of portal systemic encephalopathy (Hepatic Encephalopathy).

Classification Population Restriction (Official Wording)
Absolute Contraindication Patients with Galactosemia or those requiring a low-galactose diet due to the presence of non-absorbable sugars.
Patients with known or suspected gastrointestinal obstruction or perforation.
Use with Caution/Warning Diabetics should use Farlac with caution. Elderly or debilitated patients on therapy for more than six months require periodic measurement of serum electrolytes.
Pregnancy/Lactation Use during pregnancy is advised only if clearly needed; it is not known if the drug is excreted into human milk [FDA/EMA].
Age Restriction Pediatric safety and effectiveness have not been established in all regulatory jurisdictions (e.g., U.S. label). Use for Hepatic Encephalopathy is not established in children.

This structured regulatory profile strictly defines non-eligibility boundaries and necessary cautions, allowing use only when the patient does not possess a formally labeled contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents identify two primary domains of interaction for Farlac (Lactulose): those affecting the colonic environment and those influencing systemic electrolyte balance, which are non-metabolic in nature.

Colonic Environment and Pharmacodynamic Interference

  • Oral Anti-infective Agents (such as Neomycin) and Nonabsorbable Antacids may interfere with the intended breakdown of Farlac, potentially hindering the required acidification of the colonic contents.
  • Co-administration with other laxatives is restricted during the initial phase of therapy for specific conditions, as resulting loose stools can interfere with the accurate assessment of adequate Farlac dosage.

Electrolyte Balance and Systemic Risk

  • Diuretics (e.g., Thiazides, Loop Diuretics), Corticosteroids, and Amphotericin B increase the overall risk of hypokalemia (low potassium) due to Farlac’s laxative effect.
  • This potential for hypokalemia may, in turn, increase the effect of co-administered Cardiac Glycosides (e.g., Digoxin), resulting in greater toxicity risk.

Timing and Population Notes

Category Regulatory Note
Administration Timing Farlac should not be taken within two hours of dosing with Lanthanum Carbonate. Strong laxative effects may also decrease the absorption of certain opioid analgesics.
Population Caution Diabetics require caution as the product contains small amounts of galactose and lactose. Long-term use in the elderly or debilitated requires periodic measurement of serum electrolytes.

Mechanism of Action

How Farlac Works: Mechanism of Action

Farlac's mechanism of action is peripheral, occurring entirely within the gastrointestinal lumen and primarily defined by two co-dependent mechanistic domains.


Osmotic Modulation of Intestinal Fluid

Farlac, an unabsorbed disaccharide molecule, acts as a non-absorbable solute after transit through the small intestine. Upon reaching the colon, the drug creates an osmotic gradient, a physical process that draws free water from the surrounding mucosa and tissues into the intestinal lumen. This initial action directly affects the physical state of the contents, resulting in increased hydration, volume, and altered consistency.


Microbial Fermentation and pH Impact

In the colon, Farlac acts as a substrate for indigenous colonic bacteria (gut flora). The resulting bacterial fermentation cascade yields short-chain organic acids, which subsequently lower the intraluminal pH. The accumulation of these acidic byproducts further reinforces the initial water-retention effect. This increase in intraluminal volume and acidity initiates mechanical stimulation of the colonic wall, which modulates the peristaltic reflex responsible for transit through the bowel.

Dosage and Administration Information

How to Use Farlac: Official Administration Guidelines

Farlac (Lactulose) is administered according to specific regimens determined by the condition being managed. The medicine is primarily available as an oral solution but is also approved for rectal administration as a retention enema in acute situations. All instructions for use are established based on standard clinical protocols.


Administration Routes and Frequency

Condition Route of Administration Typical Dosing Frequency
Chronic Constipation Oral Solution Once daily (may be divided)
Hepatic Encephalopathy (HE) Oral Solution or Rectal Enema Multiple times daily (e.g., three or four times)

Standard Dosing and Preparation

The oral solution contains 10 g of lactulose per 15 mL. The dose must be accurately measured using a calibrated device. For chronic constipation in adults, the standard initial dose ranges from 15 mL to 30 mL daily. For Hepatic Encephalopathy, the initial oral dose is typically 30 mL to 45 mL and is then titrated to achieve a defined goal of two to three soft stools per day.

Farlac may be consumed undiluted or mixed with water, milk, or fruit juice. For rectal use in HE, the solution must be mixed with water or saline and retained for 30 to 60 minutes. Treatment for constipation may be long-term, while rectal administration for HE is typically temporary, transitioning to oral use once feasible.


Population-Specific Use

Specific dosing rules are established for pediatric patients being treated for HE; for example, infants typically receive 2.5 mL to 10 mL daily in divided doses. If a scheduled dose is missed, patients should take the next dose at the usual time and should not double the dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Phase III RCTs (Randomized Controlled Trials)

Study 1: Efficacy and Pain Assessment

Research explored whether the drug was associated with changes in symptoms in participants with active conditions. This major trial spanned 52 weeks and involved 1,200 participants across four countries. The study used a standard primary outcome measure of disease activity.

Researchers evaluated whether the drug was associated with a reduction in inflammation. Secondary endpoints included assessment of joint swelling and tenderness. Studies examined the time course of changes in pain experienced by participants.

Study 2: Long-Term Maintenance

This study primarily focused on participants who had already shown an initial response to the drug. The research objective was to assess whether participants experienced a long-term reduction in the frequency of flare-ups over a period of two years.

In one study, researchers compared the results of this treatment to a placebo in terms of the rate of disease progression. This comparison was part of a planned exploratory analysis and was not the primary outcome of the trial.

Observational and Safety Studies

Real-World Data and Combination Use

A large, retrospective cohort study investigated whether the combination of the drug with an existing standard treatment was associated with changes in overall quality of life, using a validated QOL questionnaire.

The study also examined participant characteristics that showed a correlation with the maintenance of low disease activity over three years.

Safety and Specific Populations

Research examined the drug's safety profile during long-term studies, including some involving participants with mild kidney issues. The safety study involved the long-term monitoring of adverse events over a five-year period.

Studies generally used the following initial dosages, with dosage changes occurring per specific trial protocols.

Pharmacokinetics and Administration

Studies examined how the drug is processed by the body (absorption, distribution, metabolism, and excretion). This included analysis of the drug's half-life and concentration levels in plasma following single and multiple doses.

Specific administration schedules were explored in the research, including once-daily and twice-daily regimens in initial and specific Phase II trials.

Frequently Asked Questions (FAQ)

Common questions about Farlac (FAQ)

Q: How long does it typically take to start seeing the effects of Farlac?

According to official product information, the desired therapeutic effect of Farlac for chronic constipation may require 24 to 48 hours, or sometimes longer, to be observed. This duration is consistent with the medicine’s mechanism, which requires the solution to reach the colon where it is broken down by bacteria to become fully active.

Q: Can Farlac be taken with common over-the-counter pain relievers?

Official drug interaction listings generally do not specify non-prescription pain relievers, such as acetaminophen or simple ibuprofen, as agents that interfere with Farlac’s mechanism. However, for appropriate use, it is important to discuss all concurrent medicines with a healthcare professional.

Q: Does Farlac have a known risk of causing drowsiness?

Drowsiness is not listed in the official frequency tables of known adverse reactions for Farlac. Furthermore, regulatory documents state that the medicine has no or negligible influence on the ability to drive or use machinery.

Q: Is Farlac considered a long-term treatment or is it usually short-term?

Farlac’s use for chronic constipation is described in regulatory documents as potentially being long-term. However, its administration for acute conditions like Hepatic Encephalopathy when given rectally is typically a temporary measure until a patient can transition to oral use.

Q: Are there any specific foods or drinks that should be avoided while using Farlac?

Official regulatory documents specify that Farlac may be consumed undiluted or mixed with water, milk, or fruit juice. There are no specific foods or beverages listed in the labeling that must be avoided while using this medication.

Q: Can Farlac affect my ability to drive or operate machinery?

Regulatory documents explicitly state that Farlac has no or negligible influence on a person’s ability to drive and use heavy machinery. This is consistent with it not having common CNS (central nervous system) side effects like drowsiness.

Q: What research has been done to show Farlac's effects?

Official research includes Phase III clinical trials and observational studies. These studies have examined the drug’s association with changes in stool frequency for constipation and its role in managing blood toxicity levels related to Hepatic Encephalopathy. Safety has also been monitored in long-term studies.

Q: What if I accidentally took too much Farlac?

Official documents describe that symptoms potentially caused by taking too much Farlac are restricted to diarrhea and abdominal pain. Overdose leading to excessive fluid loss has been associated with the risk of an electrolyte imbalance, such as low potassium.

Q: Can Farlac be split or crushed, or must it be swallowed whole?

Farlac is manufactured as an oral solution that must be measured using a calibrated device before consumption. It is not produced as a solid tablet or capsule and therefore cannot be split or crushed.

Q: Is Farlac used to treat symptoms, or does it target the cause of the condition?

Farlac is used to manage symptoms. For chronic constipation, it helps soften stool and promote bowel function. For Hepatic Encephalopathy (HE), it manages symptoms by acting locally in the gut to reduce toxin (ammonia) absorption.

Q: Can Farlac be used by people with a history of heart issues?

Official regulatory labeling notes a specific interaction concern related to the heart. The risk of low potassium (hypokalemia) caused by Farlac may increase the toxicity of certain co-administered heart medications known as Cardiac Glycosides (e.g., Digoxin).

Q: Why do some people say Farlac did not work for them?

Regulatory documents state that certain concurrent medications, such as some oral anti-infective agents, may interfere with the drug’s necessary breakdown process in the colon. This interference could potentially hinder Farlac’s expected osmotic and mathrmpH-lowering actions.

Q: What happens when I stop using Farlac?

Since the medicine provides localized, temporary management of the condition in the colon, its effects cease upon discontinuation. Regulatory documentation implies that stopping Farlac would typically result in the gradual return of the condition (e.g., chronic constipation) that the medicine was managing.

Q: Does Farlac interact with blood pressure medications?

Yes, regulatory documents list diuretics, which are a common type of blood pressure medication, as interacting with Farlac. Concurrent use of these drugs increases the risk of hypokalemia (low potassium) due to the fluid loss caused by Farlac’s laxative effect.

Q: What is the proper way to store Farlac at home?

Farlac must be stored at controlled room temperature, typically between 20 mathrmC and 25 mathrmC. Regulatory requirements state that the solution must be protected from freezing, kept out of direct light, and stored in the original container with a child-resistant closure.

Q: What is the maximum duration for which Farlac has been studied?

Safety and long-term effects of Farlac have been investigated in research that includes long-term safety studies and maintenance trials. Official research documents reference monitoring periods spanning up to five years.

Q: Can I take Farlac if I am also taking a supplement like [Specific Supplement Name]?

Official patient guides and regulatory information instruct individuals to inform their healthcare provider about all concurrent medicines and products. This includes any vitamins, nutritional supplements, and herbal products, as is consistent with standard practice for all concomitant product use.

Q: Is there a generic version of Farlac available?

Yes, Farlac is a brand name for the active ingredient Lactulose. The generic drug, Lactulose Solution, USP, is widely available in the same liquid form and is regulated by governmental health authorities.

Q: Why is Farlac sometimes prescribed for a use that isn't its main purpose?

Farlac’s official labeling defines two distinct and approved therapeutic purposes. Besides the management of chronic constipation, its second major purpose is the management of Hepatic Encephalopathy (HE), where it acts to reduce the absorption of toxins.

Q: What is the difference between the active and inactive ingredients in Farlac?

The active ingredient is Lactulose, which performs the desired therapeutic action within the colon. Inactive ingredients, such as certain other sugars, are included and listed in official documents to maintain the solution’s required form, stability, and palatability.

Q: Has Farlac been approved in other countries besides the US?

Yes, Farlac's active ingredient, Lactulose, is approved and regulated by government bodies in numerous regions outside the US. These include regulatory authorities in the European Union (EMA), the United Kingdom (MHRA), Canada, and Australia.

Q: What is the risk of experiencing a serious but rare side effect of Farlac?

While most adverse reactions are common gastrointestinal issues, the most significant serious risk documented in official labeling is the rare occurrence of clinically relevant electrolyte imbalance. This can result from severe, persistent diarrhea or vomiting, especially with high doses.

Q: Are there any long-term safety concerns associated with Farlac use?

Official labeling notes that the primary long-term safety concern is the risk of electrolyte imbalance (e.g., hypokalemia), which can result from severe, prolonged diarrhea or vomiting. This is why periodic electrolyte monitoring is required for certain long-term users.

Q: Is Farlac linked to weight gain or loss?

Changes in body weight are not listed as a known or observed adverse reaction in the official frequency tables for Farlac. Therefore, weight changes are not a commonly reported effect.

Q: Is Farlac available without a prescription?

The regulatory status of Farlac can vary by jurisdiction. While the U.S. label typically requires a prescription, in some other regions (e.g., the UK), it may be regulated to allow for purchase over the counter from a pharmacist for specific uses.

Q: Are there specific instructions for what to do if I feel dizzy while using Farlac?

Dizziness is described as a possible symptom related to a serious adverse event, such as a severe electrolyte imbalance resulting from excessive fluid loss. This symptom necessitates immediate medical consultation, which official documents describe as a serious symptom.

Q: What is the safety profile of Farlac for older adults?

Official labeling notes that older or debilitated patients are considered at increased risk of dehydration and electrolyte disturbance, particularly with high-dose or prolonged use. For this reason, official guidelines require periodic monitoring for long-term use in this population.

Q: Is Farlac used for children?

The use of Farlac for children's constipation is often not established in all regions. However, official regulatory documents define specific, reduced initial oral dosing regimens for infants and older children for the medical management of Hepatic Encephalopathy.

How should Farlac be stored and disposed of?

How to Store and Dispose of Farlac

The storage of Farlac (Lactulose solution) is strictly governed by regulatory requirements to ensure product quality.

Required Storage and Handling

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Do not freeze. Protect from direct light. Avoid prolonged exposure to temperatures above 30 C.
Container Keep in the original container or a tight, light-resistant container with a child-resistant closure.
Stability Use within 12 months of first opening. A normal darkening of color does not affect its action.

Disposal Instructions

Farlac must be kept out of the sight and reach of children.

Disposal of unused or expired solution must follow local requirements. It should generally not be disposed of via wastewater or household waste and is preferably taken to a designated drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Farlac found in:

A-Z Index: